Unique ID issued by UMIN | UMIN000026920 |
---|---|
Receipt number | R000030882 |
Scientific Title | Evaluation of the effectiveness of the orexin receptor antagonist for type 2 diabetes with sleep disorder upon glycemic control. |
Date of disclosure of the study information | 2017/04/17 |
Last modified on | 2018/02/05 07:09:18 |
Evaluation of the effectiveness of the orexin receptor antagonist for type 2 diabetes with sleep disorder upon glycemic control.
Evaluation of the effectiveness of the orexin receptor antagonist for type 2 diabetes with sleep disorder upon glycemic control.
Evaluation of the effectiveness of the orexin receptor antagonist for type 2 diabetes with sleep disorder upon glycemic control.
Evaluation of the effectiveness of the orexin receptor antagonist for type 2 diabetes with sleep disorder upon glycemic control.
Japan |
type 2 diabetes
Endocrinology and Metabolism |
Others
NO
Evaluation of the effectiveness of the orexin receptor antagonist for type 2 diabetes with sleep disorder upon glycemic control.
Safety,Efficacy
changes of validation by continuous glucose monitor (CGM)
changes of CES-D12, SF-8, parameters related to lipid, hepatic function and diabetes mellitus, 1 week later
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
1
Treatment
Medicine |
administration of suvorexant
25 | years-old | <= |
80 | years-old | > |
Male and Female
1.Adults who are 25 years or older and 80 years or younger
2.Type 2 diabetes patients
3.HbA1c 6.0% to 10.0%
4.Patients below BMI 35kg/m^2
5.Patients with Pittsburgh score 5.5 points or more
6.Patients who can understand consent sufficiently and having the agreement regarding participation in this examination
1.Patients who are diagnosed type2 diabetes within 6 months
2.Patients who are not considered to take a general levels of diet therapy
3.Patients who take considerable levels of exercise
4.Excessive common custom drinker
5.Patients with severe liver disease
6.Patients who had severe hypoglycemia within 3 months
7.Patients who had a record of Anti-GAD Antibody positive
8.A pregnant woman or the woman who may be pregnant
9.Patients who are breastfeeding
10.Patients who take medications on a sleep disorder
11.Patients who will be considered inappropriate by an attendant physician
20
1st name | |
Middle name | |
Last name | Takuya Ishikawa |
Toda Chuo General Hospital
Internal Medicine
1-19-3 Honmachi, Toda, Saitama 335-0023, Japan
0484421111
tactash@yahoo.co.jp
1st name | |
Middle name | |
Last name | Takuya Ishikawa |
Toda Chuo General Hospital
Internal Medicine
1-19-3 Honmachi, Toda, Saitama 335-0023, Japan
0484421111
tactash@yahoo.co.jp
Toda Chuo General Hospital
Self funding
Self funding
NO
2017 | Year | 04 | Month | 17 | Day |
Unpublished
Terminated
2017 | Year | 04 | Month | 17 | Day |
2017 | Year | 04 | Month | 24 | Day |
2017 | Year | 04 | Month | 10 | Day |
2018 | Year | 02 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030882
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |